4 April, 2014. Biotecnol has announced that it has entered into a Research and Collaboration Agreement with ICVS of the University of Minho in Portugal. ICVS is a renowned for its high-level research activities and incorporates the Clinical Academic Center – Braga (CCAB), which results from a partnership between the University of Minho and the Hospital of Braga, with a focus on research, education, training and caring in a clinical setting. The CCAB is in a privileged position to ally basic and clinical research, maximizing the development of innovative biomaterials, diagnostic strategies, regenerative approaches and therapeutic products. With basis on this health ecosystem infrastructure, the CCAB seeks to strengthen the UMinho position as a leader in bioscience innovation and translational research.
Biotecnol is entering into a variety of pre-clinical translational research activities with ICVS and is carrying pre-clinical work in a variety of disease settings, with a focus on highly-heterogeneous tumour types, where T-cell based targeted approaches have shown promising results, which are encouraging the development of new therapeutic products in the immuno-oncology setting.
Biotecnol is an immune-oncology company with a strong track-record in antibody drug development. The company has a proprietary antibody format -Tribody™- for engaging various immunological effector functions including T-cells, to destroy cancer cells. The Company is looking to strengthen this solid asset base of new agents in the immune-oncology field, by developing candidates with a dual approach involving novel targets. Biotecnol has fully integrated capabilities that allow the company to run and effectively manage its own drug development programmes, right from the antibody selection process to clinic proof of concept.
The Life and Health Sciences Research Institute (ICVS) was created in 2003 and aims at improving human health through outstanding life-science research, cutting-edge medical innovation and delivery of specialized services. The ICVS is a R&D Unit incorporated in the School of Health Sciences (ECS) - University of Minho, strategically located in the Northern region of Portugal within a fast growing Cluster of Biomedical Science, Technology and Healthcare institutions, being organized around three interdisciplinary Research Domains: Microbiology and Infection, Neurosciences and Surgical Sciences.
In the framework of the its R&D network, the ICVS has been consecutively evaluated by international panels with the maximum rank of “Excellent” and benefits from the guidance of a panel of renowned international scientific advisors. More than 250 researchers with complementary academic backgrounds are presently working at the ICVS. The biomedical, translational and clinical research results in more than 100 publications/year in international top-level scientific journals. Many of the ICVS researchers, including young scientists and MDs, have been honoured with awards for their scientific achievements.Back to news